Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …

Background There are many complex and rare mutations in the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …

Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …

Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …

Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the
detection of actionable mutations, which has revolutionized the treatment paradigm in this …

Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …

Background After the discovery of somatic mutations in the tyrosine kinase domain (exons
18–24) of the epidermal growth factor receptor (EGFR) correlating with responses of non …

Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …